中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2013年
10期
105-106
,共2页
曲安奈德%年龄相关性%黄斑变性
麯安奈德%年齡相關性%黃斑變性
곡안내덕%년령상관성%황반변성
Triamcinolone acetonide%Age-related%Macular degeneration
目的:观察玻璃体眼内注射曲安奈德(TA)在年龄相关性黄斑变性中的疗效.方法:确诊为年龄相关性黄斑变性的患者30例45眼,给予眼内注射TA注射液4 mg(0.1 ml).术后1、3、6个月定期随访,观察患者术后视力变化及新生血管膜大小改变,并对药物本身相关的潜在并发症进行监测.结果:11例患者(单眼患者5例,双眼患者6例)17眼完成术后6个月的随访,视力<0.1者4眼,0.1~0.5者11眼,>0.5者2眼.36眼术后视力有所提高,15眼视力达0.5以上.术后6个月的随访,17眼的新生血管膜面积明显缩小,但与术后3个月的随访相比,无明显变化.结论:曲安奈德眼内注射治疗AMD是安全有效的,并且在术后三个月时效果最佳.
目的:觀察玻璃體眼內註射麯安奈德(TA)在年齡相關性黃斑變性中的療效.方法:確診為年齡相關性黃斑變性的患者30例45眼,給予眼內註射TA註射液4 mg(0.1 ml).術後1、3、6箇月定期隨訪,觀察患者術後視力變化及新生血管膜大小改變,併對藥物本身相關的潛在併髮癥進行鑑測.結果:11例患者(單眼患者5例,雙眼患者6例)17眼完成術後6箇月的隨訪,視力<0.1者4眼,0.1~0.5者11眼,>0.5者2眼.36眼術後視力有所提高,15眼視力達0.5以上.術後6箇月的隨訪,17眼的新生血管膜麵積明顯縮小,但與術後3箇月的隨訪相比,無明顯變化.結論:麯安奈德眼內註射治療AMD是安全有效的,併且在術後三箇月時效果最佳.
목적:관찰파리체안내주사곡안내덕(TA)재년령상관성황반변성중적료효.방법:학진위년령상관성황반변성적환자30례45안,급여안내주사TA주사액4 mg(0.1 ml).술후1、3、6개월정기수방,관찰환자술후시력변화급신생혈관막대소개변,병대약물본신상관적잠재병발증진행감측.결과:11례환자(단안환자5례,쌍안환자6례)17안완성술후6개월적수방,시력<0.1자4안,0.1~0.5자11안,>0.5자2안.36안술후시력유소제고,15안시력체0.5이상.술후6개월적수방,17안적신생혈관막면적명현축소,단여술후3개월적수방상비,무명현변화.결론:곡안내덕안내주사치료AMD시안전유효적,병차재술후삼개월시효과최가.
Objective:To investigate the eficacy of intravitreous injection with triamcinolone acetonide.Method:Forty-five eyes in 30 patients, with the disease confirmed by ophthalmoscopy and fundus fluorescein angiography were given intravitreous injection with triamcinolone acetonide of 4 mg(0.1 ml).Patients were follow up 1,3,6 moths after the treatment The vision and the areas of choroidal neovascularization(CNV),and observate the potential drug complications.Result:17 eyes in 11 patients were follow up 6 moths. The visual acuity of 4 eyes was<0.1,the visual acuity of 11 eyes was 0.1-0.5,the visual acuity of 2 eyes was>0.5. The visual acuity of 36 eyes improved.The visual acuity of 15 eyes was>0.5.The areas of CNV was siginificantly decrease after 6 months.But there was no siginificantly better decrease than 3 months of postoperation.Conclusion:Intravitreous injection with triamcinolone acetonide may be effective and safely in treating age-related macular degeneration,and is the best effective in 3 months of postoperation.